← Leaderboards
David Paul Nichols
National Jewish Health
$2,763,272
Attributed
$2,763,272
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $817.2K · FY2015–19$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$2,763,272 · 1
By mechanism
R01$2,763,272 · 1
Top collaborators
No co-investigators on record.
Most similar at National Jewish Health
Same institution · by research overlap
- Monica Kraft$36,612,836
- Richard J Martin$13,509,122
- Gregory Paul Downey$7,242,854
Others in their field
Top investigators on “Communities”
- Eric S Lander · Whitehead Institute For Biomedical Res$547,749,172
- David Heimbrook · Leidos Biomedical Research, Inc.$526,770,200
- Larry Arthur$517,751,165
- Lawrence Corey · Fred Hutchinson Cancer Center$484,622,485
- David R. Weir · University Of Michigan At Ann Arbor$394,331,036
- Albert Lazzarini · California Institute Of Technology$381,143,533
Research focus
CommunitiesConsensusAminoglycosidesClinical TrialsAntibiotic TherapyAnimalsAnti-Bacterial AgentsAztreonamAntibioticsBaseBinding SitesBiologicalAntimicrobialCaringAzithromycinCaucasiansChronicClinical CareClinically SignificantBacteriaClinical PracticeClinical ResearchClinical TreatmentCystic Fibrosis
Grant awards (4)
A prospective trial of oral azithromycin when added to inhaled tobramycin in CF$600,809
R01 · FY2019 · HL · contact PI
A prospective trial of oral azithromycin when added to inhaled tobramycin in CF$627,176
R01 · FY2017 · HL · contact PI
A prospective trial of oral azithromycin when added to inhaled tobramycin in CF$718,089
R01 · FY2016 · HL · contact PI
A prospective trial of oral azithromycin when added to inhaled tobramycin in CF$817,198
R01 · FY2015 · HL · contact PI